Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Oncotest, Debiopharm announce successful biomarker projects
June 2013
SHARING OPTIONS:

LAUSANNE, Switzerland—Oncotest GmbH and Debiopharm Group have announced the completion of the first biomarker projects at Oncotest. A recent study generated pharmacological data with Debiopharm's investigational compound in Oncotest's 3D assay system for patient-derived xenografts, which was then correlated with Oncotest's genomic and transcriptomic data, resulting in the identification of several predictive biomarker candidates, including a gene signature.
 
 
"Reliable preclinical models are key success factors in drug development. We believe that technologies based on the direct use of patient tumors have game-changer potential in translational research in oncology," Dr. Hiroaki Tanaka, personalized medicine director at Debiopharm, said in a press release. "We are happy to collaborate with Oncotest … and we are looking forward to extending our partnership even further towards the achievement of personalized medicine."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.